Galapagos: This opportunity will self-destruct in 60 days

BUY, Fair Value EUR61 vs. EUR57 (+10%)
News published on August Tuesday 11, 2015
Share on

Galapagos released filgotinib’s 24w data from DARWIN-2 study in patients with an inadequate response to methotrexate who are DMARDs naïve. At 24w, filgotinib as a monotherapy showed good efficacy and a safety profile consistent with what was previously observed at 12w. These results trigger a 60-days opt-in period for ABBV.


The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities